skip to content
CMS Buy Now
Detailed Quote
5i Report
Rating
B+

Review of Knight Therapeutics

NOV 28, 2019 - Knight makes an acquisition of a Latin American pharmaceutical company and turning a significant portion of its own idle (cash) assets into a fully operating business. The company looks well set up for the future. Rating maintained at 'B+'.

Download Report
Company Profile
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions

Q: I am trying to quantify the new political risk owning this name. With the transaction for GBT being in Brazilian Reals I expect most of its revenue is in Brazil, however your report mentions Argentina and Chile as potentially unstable and there is a total of 10 Latin countries it operates in.
Can you break down the revenue sources for GBT by country please?

Read Answer Asked by Jeff on December 09, 2019
Insiders
https://research-5iresearch.lpages.co/free-trial-5i-research-5i-blog/
Share Information
News and Media